Joshua Trafton
Optometrist · Tallahassee, FLNPI 1275693848
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.9% of the total across 206 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by Alcon at 32.0% of the total.
Across 206 payments — averaging $23.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$2K
- AbbVie$602
- Johnson & Johnson Vision Care, Inc.$459
- Tarsus Pharmaceuticals, Inc.$434
- Bausch & Lomb Americas Inc.$423
- Amgen$273
- plus $1K from 13 others
What the payments were for
- Food & beverage$4,61396%
- Education$180%
- Gifts$1814%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 73 | $1,539 |
| AbbVie(2 entities) | 29 | $602 |
| Johnson & Johnson Vision Care, Inc. | 14 | $459 |
| Tarsus Pharmaceuticals, Inc. | 17 | $434 |
| Bausch & Lomb Americas Inc. | 25 | $423 |
| Amgen(2 entities) | 4 | $273 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $270 |
| Visionary Optics LLC | 1 | $160 |
| Sun Pharmaceutical Industries Inc. | 6 | $155 |
| Novartis | 9 | $134 |
| Coopervision Inc. | 4 | $117 |
| ABB Con-cise Optical Group LLC | 8 | $51 |
| Dompe US, Inc. | 2 | $51 |
| Harrow Eye, LLC | 2 | $44 |
| Thea Pharma Inc. | 2 | $28 |
| The Walman Optical Company | 1 | $21 |
| Biotissue Holdings Inc. | 1 | $18 |
| Kala Pharmaceuticals, Inc. | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TOTAL30$243
- TEPEZZA$233
- Acuvue$141
- DAILIES$117
- BIOTRUE$113
- ULTRA$113
- BIOTRUE ONE DAY$113
- Rhopressa$112
- Rocklatan$112
- DAILIES TOTAL1$107
- Precision 1$107
How this compares
$4,812 in reported general payments places this provider in the 85th percentile of 3,166 optometrist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 80 | $86,401 |
| XiidraLifitegrast | 19 | $31,267 |
| XdemvyLotilaner | 11 | $20,153 |
| LumiganBimatoprost | 23 | $8,398 |
| Latanoprost | 438 | $6,187 |
| Cyclosporine | 22 | $6,166 |
| Prednisolone Acetate | 83 | $3,357 |
| BetimolTimolol | 12 | $1,916 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 68 | $1,341 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 24 | $940 |
| Dorzolamide Hcl | 36 | $908 |
| Timolol Maleate | 74 | $725 |
| Doxycycline Hyclate | 42 | $628 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 39 | $491 |
| Brimonidine Tartrate | 27 | $332 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $602 | $94,799103 claims |
| Bausch & Lomb Americas Inc.Xiidra | $423 | $31,26719 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $434 | $20,15311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,166 optometrist providers in Florida.
Other optometrist in Tallahassee
- James HoffmanOrange Park$795K
- April JasperWest Palm Beach$553K
- Nora CothranLargo$505K
- Michael SluskyNorth Port$384K
- Katie SpearDefuniak Springs$361K
- Karen HoffmanOrange Park$282K
- Ashley RothMiami Beach$261K
- Jessica SteenDavie$256K
- Mark DunbarMiami$236K
- Robert DavisPembroke Pines$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.